07/23/2012 10:08:00 AM EST
Trips and Bits: An Essay on Compulsory Licenses, Expropriation, and International Arbitration
By Peter B. Rutledge *
* Professor of Law, University of Georgia School of Law.
Excerpt from Trips and Bits: An Essay on Compulsory
Licenses, Expropriation, and International Arbitration, 13 N.C. J.L. &
Tech. On. 149 (June, 2012)
In the early 1980s, the World Bank forecast that more than
1.2 million people in Brazil would contract the HIV virus by 2000. 1 That
catastrophe did not come to pass, due largely to an aggressive anti-AIDS
campaign launched by the Brazilian government. 2 Brazil's strategy contained a
variety of elements, including public education, aggressive promotion of
contraceptive, needle-exchange programs, and, most relevant for this article,
the low-cost or free provision of antiretroviral drugs to affected populations.
3 A key element to this strategy was aggressive negotiation over the price of
medication used to treat patients suffering from HIV and AIDS. 4
When the Brazilian government was unable to reach consensus
with Merck over the price for Efavirenz, a patented-HIV treatment drug, it
issued a compulsory license. 5 The license allowed Brazil to manufacture or
import a generic version of the drug. 6 Brazil's strategy put it at loggerheads
with Merck and other private companies whose products were essential to
treating the Brazilian populace. It also sparked controversy in its diplomatic
relations with the United States. Merck responded by accusing Brazil of
engaging in an "expropriation of intellectual property." 7 The United
States Trade Representative placed Brazil on its "priority watch
Through an agreement later negotiated between the parties,
Merck was supposed to receive a 1.5% royalty fee as remuneration. When Brazil
ordered Merck to transfer all technical documents necessary for the production
process, the company provided only the corresponding patent. 9 Farmanguinhos, a
Sign in with your
Lexis.com ID to access the full text of this article.
Click here to order the full text of this
article if you do not have a Lexis.com ID.
Sign in with your Lexis.com ID to access Patent Law resources on Lexis.com or any of these Mathew Bender Patent Law publications.
Click here to order Patent Law treatises/resources and Mathew Bender publications.
View the LexisNexis
Catalog of Legal and Professional Publications
here for a list of available LexisNexis eBooks.
Click here to learn more about
For more information about LexisNexis products and solutions connect with us through our corporate site.